Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
R&D Pipeline
4 min read
Latest Competitive Analysis of Novo Nordisk Drug Pipeline
17 October 2023
Novo Nordisk has nearly succeeded by relying on one metabolic domain and leveraging the power of GLP-1 alone, raising its market value from 100 billion to over 400 billion, reaching unprecedented heights on the centenary of its founding.
Drug Insights
5 min read
Unleashing the Power of eperisone hydrochloride: A Comprehensive Review on R&D Breakthroughs
17 October 2023
This article summarized the latest R&D progress of eperisone hydrochloride, the Mechanism of Action for eperisone hydrochloride, and the drug target R&D trends for eperisone hydrochloride.
Valuable Targets
4 min read
Analysis on the Clinical Research Progress of major histocompatibility complex class II
17 October 2023
Major histocompatibility complex class II (MHC II) molecules play a crucial role in the immune system by presenting antigens to CD4+ T cells.
Drug Insights
4 min read
A Comprehensive Review of erythromycin stearate's R&D Innovations and Drug Target Mechanism
17 October 2023
This article summarized the latest R&D progress of erythromycin stearate, the Mechanism of Action for erythromycin stearate, and the drug target R&D trends for erythromycin stearate.
R&D Pipeline
3 min read
Latest Competitive Analysis of Johnson & Johnson Drug Pipeline
17 October 2023
The performance of Johnson & Johnson's pharmaceutical sector is quite robust among large pharmaceutical companies, with the driving force of the two major engines - Ustekinumab and Daratumumab - being very adequate.
Drug Insights
4 min read
Pharmaceutical Insights: fluphenazine hydrochloride's R&D Progress and its Mechanism of Action on Drug Target
17 October 2023
This article summarized the latest R&D progress of fluphenazine hydrochloride, the Mechanism of Action for fluphenazine hydrochloride, and the drug target R&D trends for fluphenazine hydrochloride.
Advanced Tech.
4 min read
The development of lncRNA drugs is key to regulating the treatment of tumors and cardiovascular diseases
17 October 2023
Long noncoding RNAs (LncRNA) are a type of transcript that is over 200nt in length and does not code for proteins.
Drug Insights
4 min read
Exploring fosnetupitant's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
17 October 2023
This article summarized the latest R&D progress of fosnetupitant, the Mechanism of Action for fosnetupitant, and the drug target R&D trends for fosnetupitant.
R&D Pipeline
3 min read
Latest Competitive Analysis of Eli Lilly Drug Pipeline
17 October 2023
In the first half of 2023, Eli Lilly successfully ascended to the top of global pharmaceutical market value, especially with a short-term stock price increase of nearly 50% under such a large volume.
Latest Hotspot
3 min read
Longeveron Proclaims Outcomes of Lomecel-B™ in Phase 2a Clinical Investigation for Treating Alzheimer’s Disease
16 October 2023
Longeveron Inc. announced promising preliminary results from their Phase 2a trial with Lomecel-B™, aimed at treating mild Alzheimer’s disease.
Drug Insights
4 min read
Decoding gemcitabine hydrochloride: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
16 October 2023
This article summarized the latest R&D progress of gemcitabine hydrochloride, the Mechanism of Action for gemcitabine hydrochloride, and the drug target R&D trends for gemcitabine hydrochloride.
Latest Hotspot
3 min read
Freeline Conveys Clinical Findings from Phase 1/2 Trial for FLT201 in Gaucher Disease
16 October 2023
Freeline Therapeutics reported positive preliminary results on safety, tolerability, and enzyme action from their ongoing Phase 1/2 GALILEO-1 study evaluating FLT201, their gene therapy candidate for Gaucher disease.